Try Alerts Free   |   Login
Health Care › Pharmaceutical Preparations

SRPT Price Correlated With Financials For Sarepta Therapeutics

Free historical financial statements for Sarepta Therapeutics Inc. See how revenue, income, cash flow, and balance sheet financials have changed over 42 quarters since 2012. Compare with SRPT stock chart to see long term trends.

SRPT Stock Compared to Quarterly

SRPT Income Statement

Revenue, Net:233487000
Revenue Per Share:2.6664
Selling, General & Admin Expense:154316000
Research & Development Expense:252329000
Total Operating Expenses:444619000
Operating Income:-228093000
Income Taxes:3388000
Net Income:-231481000
Earnings Per Share, Basic:-2.65
Shares Outstanding, Basic Avg:87567857

SRPT Cash Flow

Operating Activities Net Income:
Depreciation, Depletion & Amortization:9889000
Change in Accounts Receiveable:25660000
Net Cash from Operations:-66815000
Net Cash from Operations Per Share:-0.763
Net Cash from Financing Activities:339000
Property, Plant & Equipment Purchases:9078000
Net Cash from Investing Activities:-289991000
Net Change in Cash & Equivalents:-356467000

SRPT Balance Sheet

Cash and Cash Equivalents:1946600000
Short-Term Investments:1059454000
Accounts Receivable, Net:203854000
Inventories:208095000
Total Current Assets:2469300000
Property, Plant & Equipment, Net:183292000
Total Assets:2996853000
Accounts Payable:56207000
Total Short-Term Liabilities:545566000
Total Liabilities:2270396000

Insider Trading

 
Change
Value
Transaction
SEC Form 4
Chambers Michael Andrew   Director
57,100 sh at $104
$5,963,124
Buy
Chambers Michael Andrew   Director
46,170 sh at $108
$4,999,230
Buy

Major Holders (from 13F filings)

Investment Type
Change
Value (x$1000)
increase or decrease
Vanguard Group Inc
8,420,047 sh
104,865 sh
1%
$631,166
-$18,416
Janus Henderson Group Plc
7,232,672 sh
-225,910 sh
-3%
$542,171
-$40,507
Blackrock Inc.
5,607,663 sh
60,704 sh
1%
$420,352
-$12,977
Sands Capital Management, LLC
3,711,101 sh
-1,071,850 sh
-22%
$278,184
-$95,460
Avoro Capital Advisors LLC
3,390,000 sh
255,000 sh
8%
$254,114
$9,208
Ecor1 Capital, LLC
2,868,145 sh
798,511 sh
39%
$214,996
$53,316
Wellington Management Group Llp
2,768,861 sh
88,383 sh
3%
$207,553
-$1,846
State Street Corp
2,316,483 sh
258,808 sh
13%
$173,644
$12,898
Bank Of New York Mellon Corp
1,990,927 sh
16,104 sh
1%
$149,238
-$5,035
Camber Capital Management Lp
1,850,000 sh
475,000 sh
35%
$138,676
$31,261
FMR LLC
1,666,836 sh
116,900 sh
8%
$124,946
$3,865
Goldman Sachs Group Inc
1,410,923 sh
486,867 sh
53%
$105,763
$33,575
Adage Capital Partners Gp, L.L.C.
1,265,000 sh
250,000 sh
25%
$94,824
$15,532
Farallon Capital Management LLC
1,185,051 sh
193,076 sh
19%
$88,831
$11,338
American Century Companies Inc
1,184,449 sh
365,376 sh
45%
$88,786
$24,800
Price T Rowe Associates Inc /Md/
1,163,847 sh
27,042 sh
2%
$87,242
-$1,565
Bellevue Group Ag
1,139,455 sh
-11,704 sh
-1%
$85,414
-$4,515
Geode Capital Management, LLC
1,139,383 sh
-9,287 sh
-1%
$85,408
-$4,326
JPMorgan Chase & Co
1,023,748 sh
-66,918 sh
-6%
$76,741
-$8,461
Federated Hermes, Inc.
704,100 sh
517 sh
0%
$52,779
-$2,185
COMPANY PROFILE
1. ORGANIZATION AND NATURE OF BUSINESS Sarepta Therapeutics, Inc. (together with its wholly-owned subsidiaries, “Sarepta” or the “Company”) is a commercial-stage biopharmaceutical company focused on helping patients through the discovery and development of unique RNA-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. Applying its proprietary, highly-differentiated and innovative technologies, and through collaborations with its strategic partners, the Company is developing potential therapeutic candidates for a broad range of diseases and disorders, including Duchenne muscular dystrophy (“Duchenne”), Limb-girdle muscular dystrophies (“LGMDs”) and other neuromuscular and central nervous system (“CNS”) disorders. The Company's products in the U.S., EXONDYS 51 (eteplirsen) Injection (“EXONDYS 51”), VYONDYS 53 (golodirsen) Injection (“VYONDYS 53”) and AMONDYS 45 (casimersen) Injection (“AMONDYS 45”), were granted accelerated approval by the U.S. Food and Drug Administration (the “FDA”) on September 19, 2016, December 12, 2019 and February 25, 2021, respectively. Indicated for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51, exon 53 and exon 45 skipping, respectively, EXONDYS 51, VYONDYS 53 and AMONDYS 45 use the Company’s phosphorodiamidate morpholino oligomer (“PMO”) chemistry and exon-skipping technology to skip exon 51, exon 53 and exon 45 of the dystrophin gene. Exon skipping is intended to promote the production of an internally truncated but functional dystrophin protein. As of December 31, 2021, the Company had approximately $ 2,125.8 million of cash, cash equivalents and investments, consisting of $ 2,115.9 million of cash and cash equivalents and $ 9.9 million of restricted cash and investments. The Company believes that its balance of cash, cash equivalents and investments as of December 31, 2021 is sufficient to fund its current operational plan for at least the next twelve months, though it may pursue additional cash resources through public or private debt and equity financings, seek funded research and development arrangements and additional government contracts and establish collaborations with or license its technology to other companies.

Data imported from Sarepta Therapeutics Inc SEC filings. Check original filings before making any investment decision.